(Q34313624)

1 August 2017

1 reference

title

Gabapentin enacarbil: in patients with restless legs syndrome (English)

1 reference

1 August 2017

main subject

restless legs syndrome

0 references

0 references

1

Lesley J Scott

1 reference

1 August 2017

publication date

1 December 2012

1 reference

1 August 2017

1 reference

1 August 2017

volume

26

1 reference

1 August 2017

issue

12

1 reference

1 August 2017

page(s)

1073-1083

1 reference

The use of gabapentin enacarbil in the treatment of restless legs syndrome

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

Restless legs syndrome: pathophysiology, diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

Role of gabapentin enacarbil XR in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

Dose response of Gabapentin Enacarbil versus placebo in subjects with moderate-to-severe primary restless legs syndrome: an integrated analysis of three 12-week studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

A 52-week study of gabapentin enacarbil in restless legs syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

Risk of cancer in patients exposed to gabapentin in two electronic medical record systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbil

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS40263-012-0020-3

21 January 2018

12 December 2020

A phase I, single-dose study of the disposition of 14C-radiolabeled gabapentin enacarbil in healthy male volunteers

1 reference

12 December 2020

1 reference

12 December 2020

Restless legs syndrome

1 reference

12 December 2020

Evaluation of gabapentin enacarbil on cardiac repolarization: a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome

1 reference

12 December 2020

10.1007/S40263-012-0020-3

Identifiers

DOI

1 reference

1 August 2017

1 reference